Company intelligence / Profile preview

Engichem Life Sciences

Seoul, Seoul, South Korea

Ownership: Private
Employees: ~127
Development stage: Other

Overview

The lead asset, EC-18 (mosedipimod), is a small molecule immune modulator in Phase 2 clinical trials for oral mucositis with Fast Track status from the US FDA; active in other indications (CIN, ARS, COVID-19, NASH) and exhibits safety/tolerability across trials

Therapeutic areas: RheumatologyInfectious DiseasesRare DiseasesGastroenterologyPulmonologyOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Engichem Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Engichem Life Sciences.

Explore the full profile